# Ranibizumab Plus Indomethacin

> **NCT03261635** · PHASE4 · COMPLETED · sponsor: **Università degli Studi di Brescia** · enrollment: 58 (actual)

## Conditions studied

- Macular Edema

## Interventions

- **DRUG:** Ranibizumab Injection
- **DRUG:** Indomethacin

## Key facts

- **NCT ID:** NCT03261635
- **Lead sponsor:** Università degli Studi di Brescia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-07
- **Primary completion:** 2016-12-07
- **Final completion:** 2017-07-25
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2017-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03261635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03261635, "Ranibizumab Plus Indomethacin". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03261635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*